Dr Nicola SunterResearch Associate
Email: nicola.sunter@ncl.ac.uk Telephone: +44 (0) 191 246 4392 Fax: +44 (0) 191 246 4301 Address: Northern Institute for Cancer Research
Culpin R, Pearce K, Bailey J, Pointon J, Sunter N, Bailey J, Evans P, Allsup D, Allan J, Mainou-Fowler T. MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL .
In: International Journal of Molecular Medicine . 2011, Spandidos Publications.
Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia .
In: 52nd Annual Meeting of the American Society of Hematology . 2010, Orlando, FL: Blood: American Society of Hematology.
Pratt G, Fenton JAL, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JAE, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma .
British Journal of Haematology 2010, 150 (3), 371-373.
Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk .
Nature Genetics 2010, 42 (2), 132-136.
Sunter NJ, Cowell IG, Willmore E, Watters GP, Austin CA. Role of Topoisomerase IIbeta in DNA Damage Response following IR and Etoposide .
Journal of Nucleic Acids 2010, 710589.
Allan JM, Sunter NJ, Bailey JR, Pettitt AR, Harris RJ, Pepper C, Fegan C, Hall AG, Deignan L, Bacon CM, Pointon JC, Houlston RS, Broderick P, Mainou-Fowler T, Jackson GH, Summerfield G, Evans PA, Strefford JC, Parker A, Oscier D, Pratt G, Allsup DJ. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia .
Leukemia 2010,24 4 877-881.
Allan JM, Sunter N, Hall A, Mainou-Fowler T, Jackson G, Summerfield G, Harris RJ, Pettitt A, Houlston R, Bailey J, Pepper C, Fegan C, Pratt G, Allsup DJ. A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia .
In: Blood: 50th Annual Meeting of the American Society of Hematology .2008,San Francisco, California, USA:American Society of Hematology
Di Bernardo M, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman A, Sunter N, Hall AG, Dyer M, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris R, Pettitt A, Hillmen P, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston R. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia .
Nature Genetics 2008, 40 (10), 1204-1210.
Cowell I, Sunter NJ, Singh PB, Austin CA, Durkacz BW, Tilby MJ. γH2AX foci form preferentially in euchromatin after ionising-radiation .
PLoS ONE 2007, 2 (10), e1057.
Willmore, E., De Caux, S., Sunter, N., Tilby, M.J., Jackson, G., Austin, C., Durkacz, B.W. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia .
Blood 2004, 103 (12), 4659-4665.
